Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis

被引:0
作者
T H Karlsen
K M Boberg
M Vatn
A Bergquist
J Hampe
E Schrumpf
E Thorsby
S Schreiber
B A Lie
机构
[1] Rikshospitalet-Radiumhospitalet Medical Center and University of Oslo,Medical Department
[2] Institute of Immunology,Department of Gastroenterology and Hepatology
[3] Rikshospitalet-Radiumhospitalet Medical Center and University of Oslo,1st Department of Medicine
[4] Karolinska University Hospital,undefined
[5] Christian-Albrechts University,undefined
[6] Institute for Clinical Molecular Biology,undefined
[7] Christian-Albrechts University,undefined
来源
Genes & Immunity | 2007年 / 8卷
关键词
primary sclerosing cholangitis; inflammatory bowel disease; ulcerative colitis; genetic susceptibility; human leukocyte antigen;
D O I
暂无
中图分类号
学科分类号
摘要
Approximately 80% of patients with primary sclerosing cholangitis (PSC) of Northern European origin have inflammatory bowel disease (IBD), the majority ulcerative colitis (UC). An inherent problem in interpreting positive findings in genetic association studies of PSC is thus to distinguish between factors associated with hepatobiliary versus intestinal pathology. We aimed to clarify to what extent human leukocyte antigen (HLA) class II associations in UC patients with and without PSC differ. High-resolution DRB1 and DQB1 typing was performed in 365 Scandinavian PSC patients, an independent cohort of 330 Norwegian UC patients and 368 healthy controls. HLA associations found in PSC were mostly distinct from those seen in UC, and no significant differences were noted between PSC patients with concurrent UC and PSC patients without IBD. This suggests different HLA associated genetic susceptibility to PSC and UC, and supports notions that UC in PSC may represent a distinct UC phenotype.
引用
收藏
页码:275 / 278
页数:3
相关论文
共 84 条
[1]  
Podolsky DK(2002)Inflammatory bowel disease N Engl J Med 347 417-429
[2]  
Bouma G(2003)The immunological and genetic basis of inflammatory bowel disease Nat Rev Immunol 3 521-533
[3]  
Strober W(2006)New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 367 1271-1284
[4]  
Gaya DR(1988)Hepatobiliary complications of inflammatory bowel disease Semin Liver Dis 8 201-209
[5]  
Russell RK(1980)Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology Gut 21 870-877
[6]  
Nimmo ER(2005)Review article: current management of primary sclerosing cholangitis Aliment Pharmacol Ther 21 933-948
[7]  
Satsangi J(2003)Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries Scand J Gastroenterol 38 1176-1183
[8]  
Schrumpf E(2005)Increased prevalence of primary sclerosing cholangitis among first-degree relatives J Hepatol 42 252-256
[9]  
Fausa O(2001)Epidemiology of primary sclerosing cholangitis Best Pract Res Clin Gastroenterol 15 553-562
[10]  
Elgjo K(2004)The contribution of HLA genes to IBD susceptibility and phenotype Best Pract Res Clin Gastroenterol 18 577-596